Igor Lukashevich

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. pmc Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses
    Dmitry A Moshkoff
    Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard Street, Baltimore, MD 21201, USA
    Virus Genes 34:169-76. 2007
  2. pmc Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates
    Igor S Lukashevich
    Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, United States
    Vaccine 26:5246-54. 2008
  3. pmc Early blood profiles of virus infection in a monkey model for Lassa fever
    Mahmoud M Djavani
    Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard St, Baltimore, MD 21201, USA
    J Virol 81:7960-73. 2007
  4. pmc Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation
    Igor S Lukashevich
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    J Virol 77:1727-37. 2003
  5. pmc Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever
    Juan D Rodas
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    J Med Virol 72:424-35. 2004
  6. pmc A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses
    Igor S Lukashevich
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201, USA
    J Virol 79:13934-42. 2005

Research Grants

  1. MOP/LAS chimeric vaccine against Lassa fever
    Igor Lukashevich; Fiscal Year: 2007
  2. Recombinant Yellow Fever 17D-Lassa Vaccine
    Igor Lukashevich; Fiscal Year: 2009

Collaborators

Detail Information

Publications6

  1. pmc Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses
    Dmitry A Moshkoff
    Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard Street, Baltimore, MD 21201, USA
    Virus Genes 34:169-76. 2007
    ..ML29 mutations in its genomic termini may have implications for the genetic stability and replication efficiency of ML29 reassortant...
  2. pmc Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates
    Igor S Lukashevich
    Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard Street, Baltimore, MD 21201, United States
    Vaccine 26:5246-54. 2008
    ..The ML29 reassortant is a promising vaccine candidate for Lassa fever...
  3. pmc Early blood profiles of virus infection in a monkey model for Lassa fever
    Mahmoud M Djavani
    Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard St, Baltimore, MD 21201, USA
    J Virol 81:7960-73. 2007
    ..Major transcription changes have been given preliminary confirmation by quantitative PCR and protein studies and will be valuable candidates for future validation as biomarkers for arenavirus disease...
  4. pmc Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation
    Igor S Lukashevich
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    J Virol 77:1727-37. 2003
    ..Our data confirm that acute infection is associated with weak inflammatory responses in tissues and initiates a program of liver regeneration in primates...
  5. pmc Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever
    Juan D Rodas
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    J Med Virol 72:424-35. 2004
    ..Cross protection between the two strains was observed. The three out of seven monkeys that experienced protection were also the three with the strongest cell-mediated immunity...
  6. pmc A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses
    Igor S Lukashevich
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201, USA
    J Virol 79:13934-42. 2005
    ..Detailed examination of two rhesus macaques infected with this MOPV/LAS reassortant revealed no histological lesions or disease signs. Thus, ML29 is a promising attenuated vaccine candidate for Lassa fever...

Research Grants7

  1. MOP/LAS chimeric vaccine against Lassa fever
    Igor Lukashevich; Fiscal Year: 2007
    ..Our long-range goal is to understand LAS virus pathogenesis and to develop effective treatments and vaccines. ..
  2. Recombinant Yellow Fever 17D-Lassa Vaccine
    Igor Lukashevich; Fiscal Year: 2009
    ..3. Efficacy, determine whether YF17D/LAS recombinants will effectively protect strain 13 guinea pigs against LAS virus challenge. Our long-term goal is to develop a live YF17D/LAS bivalent vaccine to control YF and LF in Africa. ..